Crystal Violet Dye Selectivity for Amyloid Oligomer Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods, such as using Thioflavin-T, struggle to selectively detect globular oligomers (gOs) and curvilinear fibrils (CFs) due to their non-selective fluorescence responses, making it difficult to distinguish between these amyloid species and rigid fibrils (RFs), which is crucial for diagnosing and understanding amyloid-related diseases like Alzheimer's.

Innovation Solution

The use of triarylmethane dyes like crystal violet, which selectively bind to gOs and CFs, allowing for their specific detection in biological samples through fluorescence assays, either in vitro or in vivo, potentially combined with Thioflavin-T for RF detection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If Thioflavin-T is used to monitor amyloid assembly kinetics, then fluorescence response is obtained for both gO/CF and RF aggregates, but selectivity between gO/CF and RF species is lost

Engineering Contradiction:
Improvefluorescence responseVSAvoidselectivity
Core Design Contradiction:
Quantity of substanceVSMeasurement precision

Solution Approach 1:

The patent segments the amyloid detection function by using two different dyes with distinct specificities: Thioflavin-T for RF aggregates and crystal violet for gO/CF aggregates. This segmentation allows independent measurement of each aggregate type, resolving the selectivity problem while maintaining fluorescence response capability for both species

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent introduces crystal violet as an intermediary dye that specifically binds to gO/CF aggregates. This intermediary enables selective detection of gO/CF species without interfering with ThT-based RF detection, allowing decomposition of total amyloid signal into distinct kinetic components

Inventive Principle:
Principle #24Intermediary (Mediator)

2Quantity of substance

If Thioflavin-T is used to detect amyloid aggregates, then both gO/CF and RF species are detected, but decomposition of kinetics into separate components becomes difficult or impossible

Engineering Contradiction:
Improveaggregate detectionVSAvoidkinetic component information
Core Design Contradiction:
Quantity of substanceVSLoss of information

Solution Approach 1:

By segmenting the detection function across two dyes with non-overlapping specificities, the patent preserves kinetic component information. ThT fluorescence tracks RF formation while crystal violet fluorescence tracks gO/CF formation, enabling separate kinetic analysis without information loss

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses feedback from dual-dye fluorescence measurements to deconvolute mixed aggregate populations. By monitoring both ThT and crystal violet signals simultaneously, the system feedbacks information about relative gO/CF and RF abundances, enabling kinetic decomposition through mathematical analysis

Inventive Principle:
Principle #23Feedback

3Device complexity

If a single dye is used for amyloid detection, then simplicity is maintained, but ability to selectively determine gO/CF presence is lost

Engineering Contradiction:
Improvedetection systemVSAvoidgO/CF selectivity
Core Design Contradiction:
Device complexityVSMeasurement precision

Solution Approach 1:

The patent segments the detection system into two parallel channels: one using ThT for RF detection and another using crystal violet for gO/CF detection. This segmentation achieves gO/CF selectivity while maintaining relative system simplicity through modular design

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent creates a multi-functional detection system where the dual-dye approach serves multiple purposes: detecting total amyloid burden, selectively quantifying gO/CF species, selectively quantifying RF species, and providing kinetic information for both aggregate types from a single experimental setup

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the selective identification of gOs and CFs, providing insights into early stages of amyloid diseases and potentially improving diagnostic tools and understanding of amyloid toxicity, as these dyes show distinct responses to the initial oligomer phase and subsequent fibril formation.

Implementation Method 1

The triarylmethane dye crystal violet (also known as tris(4-(dimethylamino)phenyl)methylium chloride, methyl violet 10B, or hexamethyl pararosaniline chloride) is a highly selective indicator of gOs and CFs

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Implementation Method 2

The most commonly used technique for monitoring amyloid assembly kinetics is the amyloid indicator dye Thioflavin-T (ThT)

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Data Source

PatentUS20220062440A1Oligomer-selective fluorescent indicator dyes
Publication Date: 2022.03.03 UNIV OF SOUTH FLORIDA
  • US20220062440A1 patent drawing
  • US20220062440A1 patent drawing
  • US20220062440A1 patent drawing

AI summary

Amyloids have been known to arise from many different proteins and polypeptides. These polypeptide chains generally form β-sheet structures that aggregate into long fibers; however, identical polypeptides can fold into multiple distinct amyloid conformations. The diversity of the conformations may have led to different forms of the prion diseases. In particular, large populations of small globular amyloid oligomers (gOs) and curvilinear fibrils (CFs) precede the formation of late-stage rigid fibrils (RFs), and have been implicated in amyloid toxicity. As disclosed herein, triarylmethane f dye crystal violet is a highly selective indicator of gOs and CFs. Therefore, disclosed herein are compositions, kits, and methods for detecting amyloids in a tissue, either in vitro or in vivo.